AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
Public ClinicalTrials.gov record NCT00606476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102. All patients enrolled in Study AAB-001-251 will receive infusions of AAB-001 (bapineuzumab), including patients randomized to placebo in Study 201 and 102. Approximately 30 study sites in the US will be involved. Each patient's participation may vary from 3 months up to 84 months depending on the date of enrollment in this study. AAB-001 (bapineuzumab) is a humanized monoclonal antibody, which binds to and potentially clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Study identification
- NCT ID
- NCT00606476
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 194 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2006 (Type not available)
- Primary completion
- Sep 2012 (Actual)
- Completion
- Sep 2012 (Actual)
- Last update posted
- Nov 25, 2013
2006 – 2012
United States locations
- U.S. sites
- 29
- U.S. states
- 20
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Janssen AI Investigational Site | Peoria | Arizona | 85381 | — |
| Janssen AI Investigational Site | Sun City | Arizona | 85351 | — |
| Janssen AI Investigational Site | Encino | California | 91316 | — |
| Janssen AI Investigational Site | Irvine | California | 92697 | — |
| Janssen AI Investigational Site | La Jolla | California | 92037 | — |
| Janssen AI Investigational Site | Los Alamitos | California | 90720 | — |
| Janssen AI Investigational Site | Sacramento | California | 95817 | — |
| Janssen AI Investigational Site | San Francisco | California | 94143 | — |
| Janssen AI Investigational Site | New Haven | Connecticut | 06510 | — |
| Janssen AI Investigational Site | Washington D.C. | District of Columbia | 20057 | — |
| Janssen AI Investigational Site | Delray Beach | Florida | 33445 | — |
| Janssen AI Investigational Site | Jacksonville | Florida | 32224 | — |
| Janssen AI Investigational Site | Chicago | Illinois | 60612 | — |
| Janssen AI Investigational Site | Indianapolis | Indiana | 46202 | — |
| Janssen AI Investigational Site | Boston | Massachusetts | 02115 | — |
| Janssen AI Investigational Site | Ann Arbor | Michigan | 48105 | — |
| Janssen AI Investigational Site | Rochester | Minnesota | 55905 | — |
| Janssen AI Investigational Site | St Louis | Missouri | 63108 | — |
| Janssen AI Investigational Site | Eatontown | New Jersey | 07724 | — |
| Janssen AI Investigational Site | New York | New York | 10032 | — |
| Janssen AI Investigational Site | Rochester | New York | 14620 | — |
| Janssen AI Investigational Site | Durham | North Carolina | 27710 | — |
| Janssen AI Investigational Site | Portland | Oregon | 97239 | — |
| Janssen AI Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Janssen AI Investigational Site | Providence | Rhode Island | 02906 | — |
| Janssen AI Investigational Site | Dallas | Texas | 75390 | — |
| Janssen AI Investigational Site | Houstan | Texas | 77030 | — |
| Janssen AI Investigational Site | Bennington | Vermont | 05201 | — |
| Janssen AI Investigational Site | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00606476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2013 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00606476 live on ClinicalTrials.gov.